For the quarter ending 2026-03-31, BRNS had -$4,663K decrease in cash & cash equivalents over the period. -$3,366K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -5,534 | -11,103 | -14,571 | -40,784 |
| Share based compensation | 556 | 696 | -415 | 187 |
| Impairment of long-lived assets | - | 1,127 | 4,667 | - |
| Impairment of goodwill | - | 0 | - | - |
| Depreciation and amortization | 856 | 909 | 901 | 4,035 |
| Non-cash lease expenses | 210 | 224 | 1,449 | 1,659 |
| Unrealized foreign exchange (gain)/loss | 1,714 | -59 | 1,186 | -4,869 |
| Change in contingent consideration | 84 | 348 | 17 | -339 |
| Non-cash interest expense | 13 | 13 | 13 | 25 |
| Deferred tax benefit | -16 | -57 | -71 | -47 |
| Profit on sale of property and equipment | 38 | -104 | 68 | 281 |
| Contract asset (including related parties) | - | - | 0 | - |
| Prepaid expenses and other current assets | -529 | -1,278 | -957 | 531 |
| Research and development incentives receivable | 149 | -3,471 | 145 | -3,091 |
| Accounts payable | 644 | -348 | -1,041 | -813 |
| Accrued expenses and other current liabilities | 2,586 | -453 | -573 | -2,767 |
| Deferred income | -1,046 | -8 | -156 | -342 |
| Operating lease liabilities | -347 | -502 | -504 | -973 |
| Net cash used in operating activities | -3,366 | -4,242 | -10,726 | -33,011 |
| Proceeds from sale of property and equipment | 55 | 2 | 451 | - |
| Purchases of property and equipment | 0 | 0 | 0 | 37 |
| Net cash provided by/(used) in investing activities | 55 | 2 | 451 | -37 |
| Proceeds from issue of ordinary shares, net of issuance costs | - | 0 | 0 | 0 |
| Issue of shares from the exercise of stock options | 0 | 0 | 0 | 2 |
| Net cash provided by financing activities | 0 | 0 | 0 | 2 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | -1,352 | 418 | -1,835 | 8,430 |
| Net decrease in cash, cash equivalents and restricted cash | -4,663 | -3,822 | -12,110 | -24,616 |
| Cash, cash equivalents and restricted cash, beginning of the period | 71,852 | 75,674 | 112,400 | - |
| Cash, cash equivalents and restricted cash, end of the period | 67,189 | 71,852 | 75,674 | - |
Barinthus Biotherapeutics plc. (BRNS)
Barinthus Biotherapeutics plc. (BRNS)